San Antonio biotech acquires U.K. wound-care company

Acelity LP President and CEO Andrew Eckert says the company's acquisition of England's Crawford Healthcare ...

Kiromic founder says Houston biotech’s move to SA nearly a done deal

Houston-based immunotherapy company Kiromic is expected this month to approve moving its headquarters ...


4th Annual SURF 2018

What: San Antonio Military Health System and Universities ResearchForum When: Thursday, June ...

SwRI 2018 International Human Performance Summit

June 30-July 1, 2018 The Summit will be hosted by Southwest Research Institute as part of its ongoing ...
SA biotech gets access to cancer institute's research network — and a wider audience
March 1, 2018

BioAffinity Technologies CEO Maria Zannes said the San Antonio company will have more opportunity for collaboration and investment moving forward. CARLOS JAVIER SANCHEZ | SABJ

San Antonio-based bioAffinity Technologies has been approved for membership in the Early Detection Research Network, an initiative of the National Cancer Institute.

The approval gives the privately held biotech — which is advancing commercialization of its first product, a lung cancer diagnostic test — entry to a coveted audience that will give it more access to expanded collaboration and potential investors. The research network brings government, academic and industry leaders together to accelerate the discovery, development and validation of biomarkers for cancer risk and early detection. 

BioAffinity President and CEO Maria Zannes said the invitation is an important step in the company's development and commercialization of the CyPath Lung early-stage cancer detection product. Membership in the exclusive group is also expected to provide bioAffinity access to resources that should help advance its work on oncological diagnostics for prostate and bladder cancers.

“The National Cancer Institute’s Early Detection Research Network is an important forum to exchange ideas, discuss cutting-edge research, establish productive collaborations and partner with clinicians and medical centers that can advance bioAffinity’s noninvasive cancer diagnostics,” Zannes told me.

She said inclusion in the network will give the company an opportunity to introduce its lung cancer test to a wider audience of medical industry leaders and policymakers who are focused on early cancer detection.

The real payoff could be exposure to more collaborative opportunities and funding.

“We have no doubt our involvement with the National Cancer Institute will lead to more collaboration,” Zannes said. “More exposure has always translated into more interest in investment.”

BioAffinity’s work with UT Health San Antonio and especially its director of research at the Department of Urology, Dr. Robin Leach, helped pave the way for entry into the cancer institute’s network.

“Leach is an internationally recognized expert in this field, and we’re very pleased that she’s interested in helping us advance that research and development,” Zannes said. “She led the effort that [resulted in] our membership.”


Stay informed. Subscribe to BioMed SA news alerts.